Another Costly Delay - 10/9/26
Oct 9, 2026 · 2 min · 4 segments
Go to Zeale.co/TheLOOP/Today for today’s entire LOOP. While you’re at it, subscribe, to get the LOOP in your inbox every morning. Again that’s…
Oct 9, 2026 · 2 min · 4 segments
Go to Zeale.co/TheLOOP/Today for today’s entire LOOP. While you’re at it, subscribe, to get the LOOP in your inbox every morning. Again that’s…
The FDA says its mifepristone safety report is expected by March 2027, and that's drawing some pro-life backlash.
Pro-life groups had urged the Trump administration to restore in-person dispensing requirements before the review concludes in March 2027, criticizing the timeline as another delay that could cost tens of thousands of unborn children their lives.
In a court-ordered status report, the agency said it expects to receive the study results by mid-December and complete its evaluation and final report by March 2027.
Susan B. Anthony Pro-Life America President Marjorie Dannenfelser criticized the update as alarming and urged the Trump administration to act before the review concludes.
"The administration must correct course," Dannenfelser said, "and most importantly, it must not wait for the study to conclude before acting.
Peer review evidence shows that the Biden administration relied on insufficient evidence and flawed assumptions when it removed the in-person dispensing requirement." In other news, Augustine Institute co-founder Jonathan Reyes returns to Focus as its new CEO.
The FDA says its mifepristone safety report is expected by March 2027, and that's drawing some pro-life backlash.
Pro-life groups had urged the Trump administration to restore in-person dispensing requirements before the review concludes in March 2027, criticizing the timeline as another delay that could cost tens of thousands of unborn children their lives.
In a court-ordered status report, the agency said it expects to receive the study results by mid-December and complete its evaluation and final report by March 2027.
Susan B. Anthony Pro-Life America President Marjorie Dannenfelser criticized the update as alarming and urged the Trump administration to act before the review concludes.
"The administration must correct course," Dannenfelser said, "and most importantly, it must not wait for the study to conclude before acting.
Peer review evidence shows that the Biden administration relied on insufficient evidence and flawed assumptions when it removed the in-person dispensing requirement." In other news, Augustine Institute co-founder Jonathan Reyes returns to Focus as its new CEO.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
